感染

订阅

MedSci主页 / 所有栏目 / 感染

Merimepodib治疗COVID-19的II期临床试验：即将开始

2020-04-26 Allan MedSci原创

Covid-19Merimepodib
关注

ViralClear制药公司已向美国FDA提交了新药研究（IND）申请，以开始Merimepodib治疗COVID-19的II期临床试验。

ViralClear制药公司已向美国FDA提交了新药研究（IND）申请，以开始Merimepodib治疗COVID-19的II期临床试验。这是一项随机、安慰剂对照的临床试验，以评估Merimepodib对COVID-19患者的疗效和安全性。20名患者将来自三个梅奥诊所：明尼苏达州罗切斯特、亚利桑那州斯科茨代尔和佛罗里达州杰克逊维尔。批准后，试验将在梅奥诊所进行，由医学博士Andrew D. Badley领导。

Merimepodib是一种广谱抗病毒药物，在实验室测试中显示出对细胞培养中的COVID-19病毒具有强活性，体外研究表明病毒产生减少了98％以上。在这项研究之前，已对Merimepodib进行了12项临床试验研究，包括5项针对丙型肝炎患者的试验、1项针对牛皮癣患者以及在健康志愿者中进行的6项试验（均为I期研究）。

 

原始出处：

https://www.firstwordpharma.com/node/1718384

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1653016, encodeId=9fda16530165e, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Mon May 04 03:19:13 CST 2020, time=2020-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088800, encodeId=6fb520888009d, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Mon Mar 15 00:19:13 CST 2021, time=2021-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931507, encodeId=699e193150e77, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Mon Dec 14 11:19:13 CST 2020, time=2020-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524802, encodeId=7f0c1524802e4, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Tue Apr 28 03:19:13 CST 2020, time=2020-04-28, status=1, ipAttribution=)]
    2020-05-04 医生2402

    #I期临床#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1653016, encodeId=9fda16530165e, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Mon May 04 03:19:13 CST 2020, time=2020-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088800, encodeId=6fb520888009d, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Mon Mar 15 00:19:13 CST 2021, time=2021-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931507, encodeId=699e193150e77, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Mon Dec 14 11:19:13 CST 2020, time=2020-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524802, encodeId=7f0c1524802e4, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Tue Apr 28 03:19:13 CST 2020, time=2020-04-28, status=1, ipAttribution=)]
    2021-03-15 839640778

    #I期临床试验#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1653016, encodeId=9fda16530165e, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Mon May 04 03:19:13 CST 2020, time=2020-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088800, encodeId=6fb520888009d, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Mon Mar 15 00:19:13 CST 2021, time=2021-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931507, encodeId=699e193150e77, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Mon Dec 14 11:19:13 CST 2020, time=2020-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524802, encodeId=7f0c1524802e4, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Tue Apr 28 03:19:13 CST 2020, time=2020-04-28, status=1, ipAttribution=)]
    2020-12-14 kksonne

    #II期临床试验#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1653016, encodeId=9fda16530165e, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Mon May 04 03:19:13 CST 2020, time=2020-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088800, encodeId=6fb520888009d, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Mon Mar 15 00:19:13 CST 2021, time=2021-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931507, encodeId=699e193150e77, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Mon Dec 14 11:19:13 CST 2020, time=2020-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524802, encodeId=7f0c1524802e4, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Tue Apr 28 03:19:13 CST 2020, time=2020-04-28, status=1, ipAttribution=)]
    2020-04-28 guihongzh

    #II期临床#

    0

相关资讯

JAMA：美国5700例COVID-19住院患者的临床特征和结局

2020年4月22日，JAMA刊登了一项最新研究《Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients

bioRxiv：一种COVID-19候选疫苗在恒河猴体内试验成功了!

导言：COVID-19在全球的爆发愈演愈烈，全世界都加速了疫苗研制的步伐。现在疫苗可能是治愈新冠病毒的唯一方法，人们迫切希望疫苗能够研发成功，能够尽快投入使用。

BMJ：COVID-19男性患者排毒时间更长，粪便中病毒存在时间超过呼吸道

患者粪便样本中SARS-CoV-2的持续时间明显比呼吸道和血清样本更长。

Circulation: 李红良团队系统介绍COVID-19的特点及其对心血管系统的影响

2020年4月15日，心血管顶级杂志Circulation在线发表了武汉大学李红良教授与加拿大渥太华大学心脏中心的PeterP. Liu教授合作的题为“The Science underl

4月23日全球新冠肺炎（COVID-19）疫情简报，确诊263万例，30个国家病例破万

据worldometers实时统计数据显示，在4月23日北京时间8：00时，全球累计确诊新冠肺炎病例2634918例，累计死亡184028例。目前已有30个国家新冠肺炎确诊病例数超万例。美国约翰斯&m

II期临床试验测试Vafidemstat治疗重症COVID-19患者的疗效

Oryzon Genomics是一家临床阶段的生物制药公司，近日宣布，该公司已收到西班牙药物管理局（AEMPS）的批准，以开展vafidemstat治疗重症COVID-19患者的II期临床试验。

拓展阅读

Front Med：COVID-19住院患者Casirivimab/imdevimab失败预测评分的开发和验证

Casirivimab和imdevimab是两种非竞争性、高亲和力的人IgG1抗COVID-19单克隆抗体，它们特异性结合COVID-19病毒刺突糖蛋白的受体结合域，从而阻断病毒进入宿主细胞。

Biomedicines：2型糖尿病住院患者COVID-19的长期预后

在T2D合并COVID-19患者中，随访观察到住院死亡率、卒中和心血管住院率增加。

Cureus：2型糖尿病状态、糖尿病并发症严重程度指数评分及其与COVID-19严重程度的关系

与非糖尿病患者相比，我们样本中的糖尿病患者发生COVID-19不良临床结果和住院死亡率的几率更高。

Lancet Infect Dis：口服VV116用于治疗轻中度COVID-19成人患者的有效性和安全性评价

目前，治疗COVID-19的医疗需求仍未得到满足，新型抗病毒药物-VV116可用于治疗轻中度COVID-19成人患者，能够显著缩短临床症状持续时间，与其他药物较少发生药物间相互作用，且安全性良好。

论文解读｜Yihua Wang教授团队新研究揭示了揭示COVID-19对肺癌治疗和研究的深远影响

该文章揭示了此次大流行对肺癌治疗、临床试验、研究活动的影响。

JAMA Intern Med：COVID-19相关急性肾损伤与长期肾脏结果

与患有其他疾病相关AKI的患者相比，COVID-AKI住院幸存者的MAKE发生率、长期肾功能下降和死亡率均显著较低。